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Enzymatic conversion ofprothrombin to thrombin is a central event in coag-
ulation. For prothrombin conversion to occur at biologically significant rates,
assembly ofthe "prothrombinase" complex is required (1). This complex includes
specific enzyme (factor Xa), a nonenzyme glycoprotein cofactor (factor Va),
calcium ions, and negatively charged phospholipids in a membrane configuration
(surface cofactor) (2, 3). As estimated from in vitro kinetic studies, lack ofany of
the latter individual components greatly decreases rates ofthrombin formation
to values inadequate for hemostasis (4). During assembly ofthe prothrombinase
complex, factor Xa binds to a site in the L chain of factor Va, which in turn is
bound to phospholipid surface cofactor. The Kd of factor Xa from factor Va
bound to surface cofactor (on platelets or lipid vesicles) is ^-10-'° M (5-7). A
100-fold increased Kd is found when factor Xa-Vacomplexes are formed without
surface cofactor (7). Therefore, factor Va associated with surface cofactor, in
effect, functions as a high-affinity receptor for factor Xa that promotes increased
enzymatic conversion of prothrombin to thrombin. Corresponding with func-
tional binding as determined by enzyme kinetics, direct binding ofradiolabeled
Xa to platelets has been shown (6) to be specific and saturable.
During blood coagulation, platelets provide membrane surface area expressing
prothrombinase cofactor activity. Cofactor activity is also on blood monocytes,
lymphocytes, and neutrophils, but apparently not on red cells (5). The platelet
and leukocyte membrane surfaces in the vascular space are continuously exposed
to factor V. In the absence ofan external source of factor V, such as plasma, the
prothrombinase complex does not assemble on circulating cells, with the ex-
ception ofplatelets (5, 6), as shown in vitro using the isolated cells and prothrom-
bin activator components.
Endothelial cells and aortic explants have been shown to promote prothrombin
activation in vitro, in the presence of Xa and Cat+ (8, 9). In addition, it has been
reported (8-10) that cultured endothelial cells synthesize factor V in vitro.
Therefore, endothelial cells, like platelets, can provide functional intravascular
binding sites for factor Xa in the absence ofadded factor V.
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By contrast with the considerable details known about coagulation in the
vascular space, molecular reactions and membrane surfaces directly involved in
extravascular activation of prothrombin to thrombin in the absence of plasma
constituents (i.e., platelets and factor V) are unknown. Mechanisms of extravas-
cular coagulation are likely to be of particular importance in the lung. The entire
cardiac output circulates through capillaries of the fragile alveolar wall, and
pulmonary inflammatory and edematous disorders are associated with fibrin
deposition as alveolar hyaline membranes (11) . We have recently shown (12) that.
after short-term culture alveolar macrophages generate factor V activity in a
process dependent on cellular maturation and protein synthesis. In the present
work, we investigate the kinetics of prothrombin activator complex assembly on
the surfaces of these cells. We find that incubated alveolar macrophages express
factor Xa receptors that promote assembly of functional prothrombin activator
complexes and high rates of thrombin formation, even at extremely low concen-
trations of factor Xa (^-10-'° M, or ^"0.1% of the factor X concentration in
blood). These studies support the thesis that, in the extravascular alveolar
compartment of the lung, macrophage factor Xa receptors participate in pro-
thrombinase complex assembly in the absence of plasma factor V during rapid
coagulation responses invoked by injury.
Materials and Methods
Cell Isolation and Culture. Alveolar macrophages were isolated from New Zealand
White female rabbits determined to be pathogen free (Hazelton, Denver, PA). The cells
were obtained by bronchoalveolar lavage and washed as previously described (12). Briefly,
animals were killed by intravenous injection of 3 ml of pentobarbital (1 g/ml). The lungs
were excised and lavaged with 80 ml of 0 .15 M sterile saline. Cells in lavage fluids were
pelleted by centrifugation and suspended at 5 X 106/ml in 0.15 M NaCl or in serum-free
medium (MEM, Flow Laboratories, Inc ., McLean, VA) with 100 U/ml of penicillin, 100
,ug/ml streptomycin, and 0.5% lactoalbumin hydrolysate heated to 56°C for 30 min before
use (Becton Dickinson & Co., Oxnard, CA). In some experiments the ionophore monensin
(13) and the protein inhibitor puromycin (14) were added to cultures at 1 gM
and 10 pg/ml, respectively. After overnight culture, alveolar macrophages were detached
using a rubber policeman and suspended in the culture medium. Viability was >95% in
preparations of freshly isolated cells and 85 ± 5% after culture, as determined by trypan
blue exclusion. Cytocentrifuged macrophage suspensions were examined directly using
phase microscopy and with transmitted light microscopy after Wright's staining. As
previously reported (12, 15), alveolar macrophages isolated as described are highly
purified. The preparations were found to be free of contamination with platelets, either
in suspension or adhering to the cells, and ^-1 % neutrophils and lymphocytes were
present.
Surfactant Isolation. Lung surfactant material was obtained from bronchoalveolar
lavage, using established methods (16). Cell-free lung lavage fluid was centrifuged at 4°C
at 8,000 g for 30 min. The pellet obtained was suspended in saline, layered over 0.7 M
sucrose, and centrifuged again. Surfactant was collected from the interface and suspended
in medium before carrying out kinetic studies of prothrombinase assembly.
Measurement ofProthrombin to Thrombin Conversion.
￿
Rates of enzymatic conversion of
prothrombin to thrombin were determined in incubation mixtures containing the sub-
strate, prothrombin, at 1 .5 1,M and factor Xa at 3.5-0.0137 nM together with nonenzy-
maticcomponents ofthe prothrombinase complex, including CaC12 (5 mM), and lipid mem-
branes provided by macrophages at 106 cells/ml. Plasma factor V/Va, when added, was
at 8-0 .8 tag/ml. In some experiments, as described in results, the cells were substituted
for surfactant or subcellular fragments. The macrophages and surfactant were at similar1904
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lipid concentration in the final mixture (^-40 nmol lipid phosphorus/150 j1), which was
composed of 46.3% phosphatidylcholine, 39.1% phosphatidylethanolamine, 4.2% phos-
phatidylinositol, 2.2% phosphatidylserine, and 5.5% sphingomyelin and lysophosphatidyl-
choline for alveolar macrophages and 74.0% phosphatidylcholine, 8 .0% phosphatidyleth-
anolamine, 10.5% phosphatidylglycerol, 7.4% phosphatidylinositol for lipid surfactant. In
some experiments with fresh alveolar macrophages, additional lipid (rabbit brain cephalin,
1 .3 ,M lipid phosphorus; Sigma Chemical Co., St. Louis, MO) was added to the mixtures.
Reagents were in 0.15 M NaCl, except cells, membranes and surfactant, which were in
buffered medium. The pH ofthe reaction mixtures was 7 .1-7 .3 . After initiating enzymatic
reactions by addition of the substrate, 10-15-jl samples were successively taken for
thrombin assay at intervals of 0 .5-5 min for periods of 15-120 min in order to follow the
reactions to completion or near completion. The samples were immediately diluted 10-
80-fold in cold saline to stop the reaction. To measure thrombin, 90 tcl of diluted sample
was added to 90 Al of fibrinogen (5 mg/ml) and one-stage clotting tests were performed
using a Fibrometer (Becton, Dickinson & Co., Cockeysville, MD). In this assay, log-log
plots of measured clotting times versus concentrations of thrombin were linear from 15-
250 s, corresponding to thrombin concentrations of 3-100 nM. Standard curves were
prepared using active-site titrated thrombin. Without the added prothrombin, factor Xa,
or lipid membrane cofactor, no thrombin activity was detected in assay mixtures.
Calculation of the Kd of Factor Xa from Macrophage and Surfactant Membranes.
Polynomial equations were derived to relate nanomolar thrombin measured in the reaction
mixtures with the respective incubation times using a multiple regression program (Regress
II, Human Systems Dynamics, Northridge, CA) on an Apple 11 microcomputer (Cuper-
tino, CA). Values of initial thrombin formation rates were calculated from the linear
coefficients of the derived equations (17). Thrombin formation rates were proportional
to low factor Xa concentrations, but approached asymptomatically to a maximum when
plotted as a function of increasing factor Xa concentrations. Double reciprocal plots of
the reaction rates versus Xa concentrations were linear, allowing calculation of the Xa
concentrations resulting in half-maximal rates (7). Because only the fraction of factor Xa
that is bound has measurable prothrombinase activity, the concentration of Xa giving half
maximal activity was taken as the Kd of Xa binding to its receptor in the prothrombinase
complex. Kinetic approaches of this type for determination of factor Xa-Va interaction
parameters have been extensively validated in studies using either artificial lipid vesicles
or platelets (6, 7).
Coagulation Factors. Coagulation factors X and II were purified to electrophoretic
homogeneity from human plasma in collaboration with Dr. George Doellgast, Department
of Biochemistry, Bowman Gray School of Medicine. Factors X and II were activated by
RVV (Russel viper venom, Sigma Chemical Co.) and TSV (Typan snake venom, Sigma
Chemical Co.), respectively, as previously reported (18, 19). Factor V was purified from
rabbit plasma by an adaptation of the method of Dahlback (20) for purification of factor
V from human plasma, including fractional precipitation with polyethylene glycol, barium
sulfate absorption, and chromatography on DEAF-shephacel followed by Sephacryl (Phar-
macia Fine Chemicals, Piscataway, NJ). The final product had a specific activity ^-1,000-
fold higher than starting plasma and corrected the clotting defect of human plasma
genetically monodeficient in factor V but not plasma monodeficient in either factor II or
X. This purified factor V analyzed by SDS-polyacrylamide electrophoresis had three bands
of ^-300,000, 200,000, and 100,000 M, . The factor V was activated 2.25-fold by catalytic
amounts of thrombin as measured in a one-stage clotting test for factor V activity using
human plasma monodeficient in factor V as substrate (20). Although rabbit factor V has
not been purified previously, considering the analogy of our results with available
information about bovine and human factor V (21, 22), it appears that our purified factor
behaves as factor V/Va (mixture of nonactivated and activated factor V).
Subcellular Fractionation.
￿
Subcellular membrane fractions from uncultured alveolar
macrophages were obtained as previously described (23, 24). Cells were lysed in 1 mM
NaHCO3 and the cellular fragments were pelleted at 2,000 g. The pellet material was
overlayered with sucrose solutions at 50, 45, 40, and 35% and fractions in interfaces wereMcGEE AND ROTHBERGER
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collected after centrifugation at 90,000 g for 2 h. The cell lysates, the supernatant from
the low-speed centrifugation and each of the fractions obtained by the 90,000 g centrif-
ugation step were analysed for lipid phosphorus content, protein concentration, alkaline
phosphodiesterase I activity and membrane cofactor activity in the prothrombinase
reaction. For the latter reaction, addition of purified factor V was necessary in that
uncultured cell lysates have negligible factor Xa receptor activity.
Antibodies.
￿
Goat antibodies to rabbit factor V were raised by innoculation of purified
factor V/Va antigen in complete Freund's adjuvant and subsequent challenge with the
antigen in saline . Immunoglobulin G containing anti-factor V was purified from the
hyperimmune serum by ammonium sulfate precipitation and DEAE chromatography (25).
The antibody obtained inhibited factor V activity in human and rabbit plasma but did not
affect activities of factors VII, X, XII, 11, VIII, or XI. Tests for individual coagulation
factors were performed using genetically monodeficient plasmas as previously described
(15, 26). In functional prothombinase tests using fresh (uncultured) alveolar macrophages
as the lipid surface, the activity in 1 jag of purified factor V/Va was 64% inhibited by 40
jig of purified anti-factor V IgG, as compared with the activity measured in the absence
of antibody. Similarly raised and isolated goat anti-human factor VII IgG and a commer-
cial purified goat nonimmune IgG were used as controls.
Miscellaneous. Protein concentrations were measured by the Lowry method using
bovine serum albumin as the standard. Lipid phosphorus concentrations were measured
by the method of Rouser et al. (27) after extracting lipids from samples by the method of
Bligh and Dyer (28). Phospholipid composition of alveolar macrophages and lipid surfac-
tant was determined using HPLC (29) by the personnel of the Lipid Core Laboratory of
the Biochemistry Department, Bowman Gray School of Medicine. Factor Xa and IIa
(thrombin) were active-site titrated using p-nitrophenyl-p'-guanidinobenzoate as previ-
ously described (18, 30). Experiments were repeated at leastthree times except subcellular
fractionation and phospholipid composition analyses, which were performed twice. Data
are presented as means t standard error.
Results
Prothrombin Activation by the Prothrombinase Complex Assembling on Alveolar
Macrophages and Surfactant. To determine whether prothrombinase complex
assembly can occur on membrane surfaces available in the alveolus, rates of
prothrombin to thrombin conversion in the presence of either isolated alveolar
macrophages or surfactant were determined. Rates were measured by quantitat-
ing concentrations of the product, thrombin, at 0 .5-2-min intervals after adding
the substrate, prothrombin (1 .5 1,M), to mixtures containing the enzyme, Xa
(3 .5 nM), Ca" (5 mM), and either freshly isolated macrophages, cultured
macrophages, or surfactant. The findings obtained demonstrate that after cul-
ture, alveolar macrophages support assembly of prothrombinase components
and thrombin generation from prothrombin at high initial rates in the absence
of exogenous factor V/Va, i.e., the cultured cells produce factor Xa-binding
sites that function like the V/Va receptor molecules described for platelets (6).
Mixtures containing freshly isolated alveolar macrophages or surfactant did not
reach similar high rates unless factor V/Va was added.
In reaction mixtures containing macrophages cultured for 20 h (0.66 ± 0.056
X 10' cells/ml), it was found that thrombin content increased linearly starting at
an incubation time of 0 s (extrapolated from ^-30 s when the first measurements
were made). The initial reaction rate was 159 ± 16 nM thrombin/min, and
conversion of prothrombin to thrombin was ^-90% complete within 15 min (Fig .
1). In mixtures containing freshly isolated (uncultured) macrophages (106
cells/ml), prothrombin conversion followed a prolonged lag (-10 min) and the1906
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FIGURE 1 .
￿
Prothrombinase complex assembly on alveolar macrophages and surfactant. Cul-
tured or freshly isolated alveolar macrophages were incubatedat 37°C in MEM, pH 7.3, with
factor Xa (3.5 nM), Ca" (5 mM), and prothrombin (1 .5 ,M) in a 150-PI mixture. Thrombin
was assayed in samples taken at the times shown (abcsissa). Lipid phosphorus concentrations
with cultured or fresh cells were 53.1 ± 4.5 and 39.43 ± 7.0 nmol (per 150 II of mixture),
respectively. Results of similar experiments with surfactant (40 nm lipid phosphorous) rather
than cells areshown in the insert (note differences of scale). The surfactant was studied fresh
andafter incubation at 37°C for 20 h underconditions comparable to those used to alveolar
macrophage culture.
measured reaction rate after this period was very low (5 ± 3 nM thrombin/min,
Fig. 1) . In studies with surfactant rather than macrophages, thrombin formation
was also found to follow lags ^-10 min, and subsequent initial reaction rates (1 .2
± 0.2 nM/min) were likewise very low (Fig. 1, inset). However, purified factor
V/Va (8 pg/ml) added to reaction mixtures containing fresh cells or surfactant
promoted efficient prothrombinase assembly, so that initial lags were notdetected
and reaction rates were high (477 ± 115 and 166.9 ± 19 nM thrombin/min,
respectively). Therefore, freshly isolated macrophages and lipid surfactant do
not have receptors for direct binding of Xa, but their membranes provide the
phospholipid cofactor indispensable for prothrombinase assembly. Addition of
rabbit brain cephalin (1 .3 AM lipid phosphorus) to mixtures containing fresh
alveolar macrophages without added V/Va did not result in significantly in-
creased levels of prothombinase activity (8.5 ± 1 .24 and 5.6 ± 0.61 nM of
thrombin/min with and without added cephalin, respectively). Incubation of
surfactant for 20 h at 37'C under thesame conditions used for culturing alveolar
macrophages had no effect on its lipid cofactor function nor on the requirement
for addition of factor V/Va to promote prothrombinase assembly (Fig. 1, inset).
Inhibition ofFunctional Factor Xa Assembly on Cultured Alveolar Macrophages by
Antibodies Raised against Plasma Factor V. Goat antibody raised against factor
V isolated from rabbit plasma was preincubated for 1 h at 37°C, with cultured
alveolar macrophages. As controls, goat anti-factor VII and nonimmune goat
IgG were used at the same concentrations as anti-factor V IgG (1 mg/ml). After
preincubation of antibody with cultured macrophages, factor Xa, prothrombin,
and Ca" were added and rates of prothrombin conversion were measured in
the reaction mixtures. Final concentration of the antibody in these mixtures was
230 ug/ml. Anti-factor V antibody was found to greatly diminish rates of
thrombin formation. By contrast, the anti-factor VII and IgG controls at theMcGEE AND ROTHBERGER
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FIGURE 2.
￿
Factor V antibody inhibition of prothrombinase assembly on cultured alveolar
macrophages. Cultured macrophages were preincubated with either anti-factor V IgG, anti-
factor VII IgG, or nonimmune IgG (1 mg/ml) for 30 min at 37°C. After this period, factor
Xa (1 .7 nM), prothrombin (1 .5 jM), and Ca" (5 mM) were added. The incubation was
continued and concentrations of thrombin in the mixtures (ordinate) was measured as for Fig.
1. Cellswere at 0.63 ± 0.02 X 106 cells/ml and final IgG concentration was 250 fag/ml.
same protein concentration had no effect (Fig. 2). This specific inhibition of
thrombin formation by antibody to plasma factor V/Va indicates that similar
antigenic reactivity is exhibited by the latter protein and the functional binding
sites for factor Xa produced by cultured alveolar macrophages.
Factor Xa Binds to Functional Assembly Sites on Cultured Alveolar Macrophages
with High Affinity. To characterize the interaction between factor Xa and its
surface receptors on culturedalveolar macrophages, rates ofthrombin formation
were measured at nine different concentrations of factor Xa (from 0.0137 to 3.5
nM) in mixtures containing fixed concentrations of the cultured cells, prothrom-
bin and Ca". Rates of prothrombin to thrombin conversion in these mixtures
increased with the Xa concentration. Aftera maximum rate was reached, further
increases in the Xa concentration did not affect the rate ofreaction significantly,
indicating saturation of the assembly sites with Xa (Fig. 3). Reciprocal plots of
measured initial rates of thrombin formation versus factor Xa concentrations
showed a linear relationship (Fig. 3), and the Kd calculated from the abscissa
intercept was 2.11 ± 0.94 X 10-'0 M.
The Kd of factor Xa binding to freshly isolated alveolar macrophages and of
Xa binding to surfactant were also measured. Neither the uncultured cells nor
surfactant amplified enzymatic effects of factor Xa significantly unless factor
V/Va was added (see above). Therefore, fixed amounts ofisolated plasma factor
V/Va were included together with varying amounts of factor Xa in the factor
Xa titration experiments. Rates ofthrombin formation also reached a maximum,
indicating membrane factor V/Va complex saturation with factor Xa. The factor
Xa interaction with uncultured macrophages and surfactant complexed with
added factor V/Va were observed to be of high affinity (Table 1). These values
resemble the Kd determined for cultured alveolar macrophages without added
factor V/Va, indicating that binding sites produced by the cells in culture are
molecules that function like plasma factor V/Va in the prothrombinase complex.
Monensin and Puromycin Inhibit Production of Factor Xa Receptors by Cultured
Alveolar Macrophages. To examine further the effect of culture on production
of the high-affinity factor Xa-binding sites, either monensin or puromycin were1908 PROTHROMBINASE ASSEMBLY ON ALVEOLAR MACROPHAGES
Factor Xa [nM]
TABLE I
The Kd of Factor Xa Binding to Alveolar Macrophages and
Comparisons with Surfactant
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FIGURE 3.
￿
Functional binding of factor Xa to V receptors on alveolar macrophages. Initial
ratesof prothrombin catalysis (ordinate) were measured in mixtures containing fixed amounts
of cultured alveolar macrophages (0.94 x 106/ml), Cat' (5 mM), prothrombin (1 .5 UM), and
concentrations of factor Xa from 3.5-0.00137 nM (abscissa). Initial reaction rates were
calculated (see Materials and Methods) from thrombin concentrations measured in samples
taken at 0.5-1-min intervals. The inserted reciprocal plot shows 1/V (initial rates) versus
1/[Xa] (factor Xa concentrations). One ofthree similar experiments is shown.
Fresh alveolar macrophages and surfactant were studied after adding
factor V/Va to assay mixtures. Cultured alveolar macrophages were stud-
iedwithout factor V/Va addition. The apparent Kd values were calculated
from intercepts on the abscissa of double reciprocal plots constructed as
indicatedin Fig. 3.TheKd values shownaremeansf standard error.The
numbers of experiments performed are indicated in parentheses.
included in the medium at 1 AM and 10 Ag/ml, respectively. Monensin has been
found to inhibit protein glycosylation and to interfere with secretory processes
in various cell types, including macrophages (13). Puromycin inhibits protein
synthesis (14). Both compounds interfered with expression offactor Xa receptors,
suggesting that the alveolar macrophage is either involved in complex metabolic
processing or in de novo synthesis of the receptor molecule (Fig. 4).
Macrophage Phospholipid Surface Cofactor for Prothrombinase Assembly Is Ex-
pressed on Cytoplasmic and Endoplasmic Membranes. Experiments were carried
out to determine whether alveolar macrophage membranes other than those on
the cytoplasmic surface can provide lipid surface cofactor. Subcellular fractions
were isolated by centrifuging macrophage lysates through a sucrose density
200-,
C
c
c
100- 1iv -
E 0
L 0.01- s H 0.005=
Kd (x 10-'° M)
Freshalveolar macrophages 6.03 ± 1.7 (3)
Cultured alveolar macrophages 2.11 ± 0.94 (3)
Lipid surfactant 8.21 ± 2.60 (5)1000
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FIGURE 4.
￿
Effect of monensin andpuromycin on factor Xa receptor production by cultured
alveolar macrophages. Rates of prothrombin to thrombin conversion in mixtures containing
alveolar macrophages cultured in the presence or absenceof 1 AM monensin (A)or 10 Ag/ml
of puromycin (B) were measured. Reagentconcentrations arethe same as for Fig. 1. Sampling
times (abscissa) and thrombin concentrations (ordinate) are shown.
gradient. The ability of each membrane fraction to serve as lipid cofactor in
assembly ofprothrombinase was determined after adjusting each fraction to the
same lipid concentration . It was found that prothrombinase activity was similar
inall fractions and when normalized permilligram ofcellularprotein, the activity
correlated highly with the respective lipid phosphorus content but not with
alkalinephosphodiesterase I activity in the fractions (Table 11). The latter enzyme
is in alveolar macrophage cytoplasmic membranes, but not in other macrophage
membranes (23). Correlation of prothrombinase activity with lipid phosphorus
(i.e., phospholipid content), rather than with phosphodiesterase (i.e., cytoplasmic
membrane content) indicates that membranes in all subcellular fractions studied
provide equally efficient phospholipid cofactor activity.
Conversion of prothrombin to thrombin is accelerated to physiologic levels by
calcium-dependent association between factor Xa (a serine protease), factor Va,
and membrane phospholipid (1). During coagulation within the circulation,
assembly of factor Xa-Va likely occurs on platelet membranes (31). Factor V in
platelets and soluble factor V in plasma are present at concentrations sufficient
to saturate factor V/Va-binding sites on platelet membranes. It is not known
which of the two factor V sources is involved in prothrombinase assembly in
vivo.
Blood leukocytes also have phospholipid surface cofactor that functions in
c a
E 0
FiE -
500
100 AM + monensin 11AM)
2 4 6 8 10 12
Time (min)
B) / AM Control
1000
_c
c
E 500
0 c AM + 10 Kg/ml puromycin
100
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TABLE 11
Correlations between Lipid Surface Cofactor Activity, Total
Phospholipid, andMembrane Marker Protein in Alveolar
Macrophage Lysates andMembrane Fractions
Subcellular fractions from uncultured alveolar macrophages were ob-
tained as described in Materials and Methods. Prothrombinase activity
in each fraction was correlated with lipid phosphorus and alkaline
phosphodiesterase activity. The respective correlation coefficients are
0.98and -0.145.
Alkaline phosphodiesterase activity, a cytoplasmic membrane marker,
was measured using thymidine 5-monophosphate-p-nitrophenyl as sub-
strate and is expressed as nmol of p-nitrophenol generated per minute
per milligramprotein.
Prothrombinase activity was measured to estimate the ability of each
fraction to provide lipid surface cofactor activity. Mixtures (150 ul)
contained 20 nmol lipidphosphorus from each fraction, 0.8,ug offactor
Va, and the rest of the prothrombinase components as in Fig. 1. Values
shown expressyM of thrombin generated permilligram of cell protein
per minute.
Lipid phosphorous is expressedas nanomolespermilligram protein and
reflects the total phospholipid content of each fraction.
prothrombin to thrombin conversion (5). Studies using radioimmunoassay have
shown that leukocytes additionally contain factor V antigen. The factor Vantigen
found within leukocytes did not promote prothrombinase assembly on these
cells, as indicated by requirements for addition of factor Va to demonstrate
enzyme activity (5).
Although there is a substantial amount of information describing possible
mechanisms of thrombin formation and coagulation on platelets within blood
vessels, there is little known about clotting factor interactions on cells or lipid
surfaces outside the vascular bed at sites removed from plasma and platelets. In
the present study, we examined a possible mechanism ofextravascularprothrom-
binase assembly in airspaces ofthe lung. Thealveolar airspace is foundto contain
fibrin deposits in a variety of inflammatory and edematous disease states, includ-
ing bacterial pneumonia, congestive heart failure, and disorders associated with
the adult respiratory distress syndrome (11, 32-34). However, molecular reac-
tions activating coagulation proteases and inducing extravascular fibrin deposi-
tion on the alveolar wall are largely unknown,
In edematous states, plasma ultrafiltrates can leak into the alveolar space
Fraction Alkaline
phospho-
diesterase*
nmol
Prothrom-
binase
activity*
p.M
Lipid
phos-
phorus¢
nmol
Alveolar macrophage lysate 70.0 4.5 369
(unfractionated)
2,000 gsupernatant 26.5 8.5 227
0/30% sucrose 0.0 34.9 4,188
30/40% sucrose 4,295.0 10.8 598
40/45% sucrose 6,705.0 9.4 616
45/55% sucrose 1,610.0 9.3 564
Pellet 569.0 2.2 222McGEE AND ROTHBERGER
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without extravasation of platelets (11, 32-34). Molecular radii and plasma
concentrations are properties influencing protein concentrations reached in
extravascular filtrates (35). Transudation offactor V, which is a large, asymmet-
ric, trace plasma protein (M, ^"300,000) across minimally damaged alveolar
capillary membranes and epithelial cell barriers would in all likelihood be
restricted as compared with passage of smaller plasma clotting proteins such as
factor VII and X (M,. ^-50,000) or large, more abundant clotting factors such as
fibrinogen. Therefore, after minimal alveolar injury, concentrations of factor V
in the airspace may be rate limiting for coagulation reactions. Requirements for
rapid extravascular clotting on the surface ofthepulmonary alveolus are evident.
In the absence of adequate hemostasis, even minimal damage of the alveolar
epithelial and endothelial barriers could result in flooding of the alveolus due to
transudation ofplasma and interstitial fluid.
Using a rabbit model in the present study, we show that alveolar macrophages
and pulmonary surfactant can directly contribute to thrombin formation, a
central event in hemostasis and coagulation reactions. We find that after a short
period of culture (several hours), the macrophages interact functionally with
factor Xa. This interaction is saturable, of high affinity (Kd - 10' ° M), and does
not require added factor V, indicating that the macrophages express receptors
for factor Xa. The prothrombinase reaction rates, Kd values and specific antibody
inhibition observed demonstrate that these receptors are functionally and anti-
genically similar to plasma factor V. Expression of the receptors is abrogated by
adding puromycin and monensin in culture, which are inhibitors of cellular
protein synthesis and processing, respectively (13, 14). The Kd of interaction
between factor Xa and alveolar macrophage receptors is similar to Kd values
reported for Xa interaction with purified factor Va added to artificial lipid
vesicles, platelets, or blood leukocyte membranes (5). It is also similar to the
reported Kd of interaction between factor Xa and intrinsic platelet factor V/Va
(6).
Additionally, we find that alveolar macrophages are sources ofsurface cofactor
activity. Cytoplasmic membranes, and membranes in subcellular fractions were
equally effective. In view ofthe fast turnover ofmacrophages in the lung (5 d in
mice) (36), the observed lipid surface cofactor on intracellular membranes may
contribute significantly to prothrombinase assembly in vivo after macrophage
death and disintegration. We also found that surfactant isolated from alveolar
lavage fluid has surface cofactor activity, but unlike alveolar macrophages,
surfactant did not express factor Xa receptor activity.
High-affinity factor Xareceptorsand surface cofactor onalveolar macrophages
may promote efficient prothrombin to thrombin conversion within the extravas-
cular airspace of the alveolus at extremely low concentrations of factor Xa,
independently ofblood platelets and plasma factor V. Further, it is possible that
factor VII, complexed with tissue factor on alveolar macrophages (12, 37),
catalyzes activation offactor X to factor Xa at cellular surface sites very near to
prothrombinase assembly, thereby minimizing exposure of nascent factor Xa to
protease inhibitors. The latter inhibitors are abundant in the lung (38). In view
ofthe ability ofalveolar macrophages to initiate the clotting sequence with tissue
factor and to facilitate thrombin formation owing to surface cofactor activity and191 2
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high-affinity factor Xa receptors, we propose the existence of an extravascular
coagulation pathway centered about these cells. Considering the apparent Kd
found forthe interaction betweenfactor Xa and macrophages (10-` o M), efficient
prothrombinase assembly could occur in the alveolus at concentrations of Xa
500-1,000-fold lower than the concentration of the factor X zymogen in plasma,
which is estimated to be ^-10-7 M in human and bovine blood (39). Therefore,
macrophages that provide a major immune defense system in the alveolus may
also be crucial for thrombin formation and coagulation reactions in the extra-
vascular alveolar space.
Summary
Efficient prothrombin activation occurs after assembly of factors Va, Xa, and
phospholipid surface cofactor as a multimolecular complex. These components
are provided by platelets and plasma within the vascular space, but molecules
and membranes for prothrombin activator assembly in extravascular spaces have
not been identified. In the present study, purified alveolar macrophages were
found to produce high-affinity factor Xa receptors that mediate formation of
enzymatic prothrombinase complexes and rapid prothrombin to thrombin con-
version in the absence of exogenous factor V/Va or platelets. Thus, in reaction
mixtures with alveolar macrophages cultured for 20 h in serum-free medium,
the thrombin formation rate was 152 nM/min/0.66 X 106 cells, after adding
prothrombin (1 .5 AM), Ca
2+ (5 mM), and factor Xa (3.7 nM). The observed Kd
of factor Xa interaction with macrophage receptors is 2.1 ± 0.94 X 10-`° M.
Kinetic analysis and inhibition studies using isolated factor V and anti-factor V
antibody show that macrophage Xa receptors are functionally and antigenically
similar to plasma factor V. By contrast, freshly isolated cells lacked receptors
promoting prothrombin conversion at high rates. Inhibitors of protein synthesis
and glycosylation, puromycin and monensin, respectively, abrogated production
of Xa receptors in culture. Additionally, subcellular fractionation and enzyme-
marker studies (alkaline phosphodiesterase 1) indicate that internal and external
membranes of alveolar macrophages have phospholipid surface cofactor activity
required for prothrombinase complexes. Pulmonary surfactant is also shown to
express this cofactor activity. Alveolar macrophages and surfactant comprise an
efficient prothrombin activator system that is independent of plasma factor V.
This system may facilitate rapid extravascular alveolar thrombin formation even
at very low concentrations of factor Xa during lung defense reactions to inflam-
mation or edema.
The authors gratefully acknowledge members of the Satellite Center of the Department
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